Bioline RX Ltd Sponsored ADR (BLRX)
NASDAQ:BLRX
Want to see BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
$2.45
-$0.02(-10.62%)
At close: 4:00 PM EST
$2.45
-$0.02(-10.62%)
Day’s Range― - ―
52-Week Range$2.15 - $7.77
Previous CloseN/A
Volume8.80M
Average Volume (3M)23.61K
Market Cap
$11.32M
Enterprise Value$18.33M
Total Cash (Recent Filing)$20.88M
Total Debt (Recent Filing)$10.15M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
May 27, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding4,351,358
10 Day Avg. Volume24,146
30 Day Avg. Volume23,614
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.63
Price to Sales (P/S)9.57
P/FCF Ratio-1.39
Enterprise Value/Market Cap1.62
Enterprise Value/Revenue15.52
Enterprise Value/Gross Profit20.66
Enterprise Value/Ebitda-10.95
Forecast
1Y Price Target
$12.00Price Target Upside389.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Marketed Product (APHEXDA) Generating RoyaltiesHaving an approved, partner-commercialized product provides a durable revenue stream via royalties/profit-share and validates the company’s commercialization capabilities. APHEXDA creates a non-dilutive income source and a platform for incremental revenue from label or geographic expansion over multiple years.
GLIX1 JV And FDA-cleared IND With Patent ProtectionThe JV and IND represent a structural shift toward internally owned, first-in-class oncology assets. Initiating human studies and extended patent coverage (to 2040) materially increase long-term upside by creating a proprietary program that can attract partners, licensing deals, or value-accretive exits if clinical proof emerges.
Improved Cash Position And Extended RunwayA multi-quarter cash runway into H1 2027, achieved via reduced burn and restructuring, gives management time to de-risk GLIX1 and motixafortide programs. This strengthens near-term financing optionality, allowing clinical progress and selective investing without immediate dilutive capital raises.
Bears Say
Severely Volatile And Collapsing RevenueA dramatic revenue decline and minimal royalties signal weak market penetration and highly volatile cash receipts. Persistent revenue instability undermines internal funding of R&D and commercialization, increasing reliance on external financing or milestone receipts to sustain operations and advance trials.
Consistent Negative Operating And Free Cash FlowStructural negative operating and free cash flow indicate the company cannot self-fund growth or clinical programs long term. Even with reduced burn, continued negative cash generation raises the probability of future equity issuance or debt, which can dilute shareholders or constrain strategic flexibility.
Moderate Leverage And Compressed Equity BaseMeaningful debt relative to a shrunken equity base limits financial flexibility if losses persist. Compressed equity and leverage raise refinancing risk and reduce the company’s ability to absorb setbacks or invest aggressively in development without incurring higher-cost financing or dilutive capital raises.
Bioline RX Ltd Sponsored ADR News
BLRX FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was $2.15 and its highest was $7.77 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Bioline RX Ltd Sponsored ADR’s market cap is $11.32M.
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is May 27, 2026 which is in 38 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Mar 23, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.115.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -1.04.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 4,351,358 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went down -12.453%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
BLRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments in R&D ventures and strong financial management, offset by minimal revenue growth and reduced operational expenses. The company's strategic focus on innovative treatments and a solid cash position are promising, but current revenue generation and market penetration remain challenges.View all BLRX earnings summariesBLRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(389.80% Upside)
Technical Analysis
Synlogic
―
Moleculin Biotech
―
Citius Pharmaceuticals
―
Chemomab Therapeutics
―
Passage Bio
―
Ownership Overview
―
Insiders
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors